Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti-High-Density Lipoprotein Antibodies in Patients with Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease

Arthritis and Rheumatology

Volumn 68, Issue 6, 2016, Pages 1367-1376

  Rodríguez Carrio, Javier ^a   López Mejías, Raquel ^b   Alperi López, Mercedes ^c   López, Patricia ^a   Ballina García, Francisco J ^c   González Gay, Miguel Á ^b,d   Suárez, Ana ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d University Hospital of Santiago de Compostela   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN ANTIBODY; IMMUNOGLOBULIN G; PARAOXON; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ARYLDIALKYLPHOSPHATASE; AUTOANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERTENSION; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; CARDIOVASCULAR DISEASES; COMPLICATION; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY;

ARTHRITIS, RHEUMATOID; ARYLDIALKYLPHOSPHATASE; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 84971247511     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39609     Document Type: Article

References (47)

1. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A., High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
2. Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, et al., Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32: 435-42.
3. Robertson J, Peters MJ, McInnes IB, Sattar N., Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013; 9: 513-23.
4. Choy E, Sattar N., Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460-9.
5. Gonzalez-Gay MA, Gonzalez-Juanatey C., Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 2014; 73: 1281-3.
6. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al., Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70: 482-7.
7. Jamnitski A, Levels JH, van den Oever IA, Nurmohamed MT., High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study. J Rheumatol 2013; 40: 825-30.
8. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al., Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2870-9.
9. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM., HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8: 222-32.
10. Mackness MI, Arrol S, Durrington PN., Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4.
11. Costa LG, Vitalone A, Cole TB, Furlong CE., Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69: 541-50.
12. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al., Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299: 1265-76.
13. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, et al., Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-72.
14. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al., A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17: 3565-9.
15. El-Banna H, Jiman-Fatani A., Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis. BMC Musculoskelet Disord 2014; 15: 379.
16. Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K, et al., Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 2003; 72: 2877-85.
17. Rodriguez-Carrio J, Alperi-Lopez M, Lopez P, Ballina-Garcia FJ, Abal F, Suarez A., Antibodies to high-density lipoproteins are associated with inflammation and cardiovascular disease in rheumatoid arthritis patients. Transl Res 2015; 166: 529-39.
18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al., 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
19. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
20. Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Palomino-Morales R, Vazquez-Rodriguez TR, Miranda-Filloy JA, Fernandez-Gutierrez B, et al., TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011; 216: 125-30.
21. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
22. Eckerson HW, Wyte CM, La Du BN., The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
23. Elfasakhany F, Mona M, Hussein M, Beyari M, Abou-Elnoeman S., Paraoxonase 1 (PON1) Glu 192 Arg gene polymorphism and serum paraoxonase activity in rheumatoid arthritis among Egyptians. Tanta Med Sc J 2010; 5: 103-10.
24. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani GR, Kordi-Tamandani DM, et al., Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res 2010; 9: 333-9.
25. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al., The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Arterioscler Thromb Vasc Biol 1998; 18: 1611-6.
26. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, et al., Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996; 57: 69-73.
27. Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J, et al., Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012; 32: 2803-12.
28. Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F., Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. Thromb Haemost 2013; 109: 854-68.
29. Batuca JR, Ames PR, Amaral M, Favas C, Isenberg DA, Delgado AJ., Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48: 26-31.
30. Rodriguez-Rodriguez L, Lopez-Mejias R, Garcia-Bermudez M, Gonzalez-Juanatey C, Gonzalez-Gay MA, Martin J., Genetic markers of cardiovascular disease in rheumatoid arthritis. Mediators Inflamm 2012; 2012:574817.
31. Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, FitzGerald J, Ranganath VK, et al., Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 2013; 65: 2765-72.
32. Lopez-Mejias R, Genre F, Corrales A, Gonzalez-Juanatey C, Ubilla B, Llorca J, et al., Investigation of a PON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2014; 73: 1749-50.
33. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al., Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-7.
34. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al., Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527-35.
35. Senti M, Tomas M, Marrugat J, Elosua R., Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler Thromb Vasc Biol 2001; 21: 415-20.
36. Senti M, Aubo C, Tomas M., Differential effects of smoking on myocardial infarction risk according to the Gln/Arg 192 variants of the human paraoxonase gene. Metabolism 2000; 49: 557-9.
37. Csordas A, Bernhard D., The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol 2013; 10: 219-30.
38. Nicholls SJ, Hazen SL., Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res 2009; 50 Suppl: S346-51.
39. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al., Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005; 7: R784-95.
40. Rodriguez-Carrio J, Alperi-Lopez M, Lopez P, Alonso-Castro S, Carro-Esteban SR, Ballina-Garcia FJ, et al., Red cell distribution width is associated with endothelial progenitor cell depletion and vascular-related mediators in rheumatoid arthritis. Atherosclerosis 2015; 240: 131-6.
41. Drechsler M, Megens RT, van ZM, Weber C, Soehnlein O., Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122: 1837-45.
42. Montecucco F, Favari E, Norata GD, Ronda N, Nofer JR, Vuilleumier N., Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions. Handb Exp Pharmacol 2015; 224: 455-82.
43. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al., Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19.
44. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al., EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
45. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, et al., Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009; 68: 868-72.
46. Corrales A, Gonzalez-Juanatey C, Peiro ME, Blanco R, Llorca J, Gonzalez-Gay MA., Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2014; 73: 722-7.
47. Arts EE, Popa C, Den Broeder AA, Semb AG, Toms T, Kitas GD, et al., Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 2015; 74: 668-74.